What TScan Therapeutics, Inc. does.

We are a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. Our lead product candidate, TSC-101, is in development for the treatment of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) who are undergoing allogeneic hematopoietic cell transplantation (HCT). The product is designed to eliminate residual disease and promote complete donor chimerism, thereby preventing relapse. TSC-101 targets HA-2, an antigen that is present on all blood cells, malignant or benign, in patients with the HLA type A*02:01. We are currently conducting a Phase 1 clinical study of TSC-101 (the ALLOHA™ trial, NCT05473910) and during the fourth quarter of 2025, following a productive End-of-Phase meeting with the U.S. Food and Drug Administration (FDA), we reached agreement on a registrational path forward for the TSC-101 program as a potential treatment for patients with AML and MDS. The pivotal study will mirror our ongoing Phase 1 ALLOHA study, using a biologically-assigned (genetically randomized) control arm to support relapse-free survival as the primary endpoint.

Revenue and profit, by fiscal year.

More on TCRX.

• TScan Therapeutics, Inc. summary
• TScan Therapeutics, Inc. financial statements
• TScan Therapeutics, Inc. key metrics
• TScan Therapeutics, Inc. health scores and style box
• TScan Therapeutics, Inc. earnings
• TScan Therapeutics, Inc. dividends
• TScan Therapeutics, Inc. valuation
• TScan Therapeutics, Inc. ownership and insiders
• TScan Therapeutics, Inc. peers

Figures from TScan Therapeutics, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.